Abstract
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionReferences
- Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins.Contraception. 2008; 78: 4-9
- The progestins.in: Goldzieher J.W. Fotherby K. Pharmacology of the contraceptive steroids. Raven Press, Ltd., New York1994: 5-19
- Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.Am J Epidemiol. 1991; 133: 32-37
- Oral contraceptives and venous thromboembolism: findings in a large prospective study.Br Med J (Clin Res Ed). 1986; 292: 526
- 20 ��g versus >20 ��g estrogen combined oral contraceptives for contraception.Cochrane Database Syst Rev. 2011; : CD003989
- Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol.Br J Obstet Gynaecol. 1979; 86: 732-736
- Natural oestrogens for oral contraception.Lancet. 1979; 2: 471-472
- A randomized, double-blind study of two combined oral contraceptives continuing the same progestogen, but different estrogens.Contraception. 1980; 21: 445-459
- Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation.Acta Obstet Gynecol Scand. 1981; 60: 203-206
- Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel.Acta Obstet Gynecol Scand. 1987; 66: 543-547
- New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women.Maturitas. 1988; 10: 201-213
- The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days.Contraception. 1996; 54: 333-338
- Oral contraceptive containing natural estradiol for premenopausal women.Maturitas. 1995; 21: 27-32
- Review of clinical experience with estradiol in combined oral contraceptives.Contraception. 2010; 81: 8-15
- Nomegestrol acetate, a novel progestogen for oral contraception.Steroids. 2011; 76: 531-539
- Why use of dienogest for the first contraceptive pill with estradiol?.Gynecol Endocrinol. 2009; 26: 109-113
- Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.Contraception. 2008; 78: 218-225
- Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.Contraception. 2009; 80: 436-444
- Qlaira: a ���natural��� change of direction.J Fam Plann Reprod Health Care. 2009; 35: 139-142
- Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial.Eur J Obstet Gynecol Reprod Biol. 2010; 149: 57-62
- Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17��-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.Eur J Contracept Reprod Health Care. 2011; 16: 430-443
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol.Eur J Contracept Reprod Health Care. 2010; 15: 314-325
- Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17��-oestradiol: a double-blind, randomised, dose-finding pilot study.Eur J Contracept Reprod Health Care. 2011; 16: 76-84
- Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17��-estradiol (NOMAC/E2): a double-blind, randomized study.Hum Reprod. 2011; 26: 1338-1347
- Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17beta-estradiol: a randomized controlled trial.Obstet Gynecol. 2012; 119: 989-999
- The neuroendocrine control of the menstrual cycle.Recent Prog Horm Res. 1980; 36: 53-88
- Dynamics of follicular growth in the human: a model from preliminary results.Hum Reprod. 1986; 1: 81-87
- Regulation of ovarian follicular development in primates: facts and hypotheses.Endocr Rev. 1996; 17: 121-155
- The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development.J Clin Endocrinol Metab. 1998; 83: 1292-1298
- Progesterone production.in: Gual C. Progress in endocrinology: Excerpta Medica. 1969: 871-879
- The utilization of plasma androstenedione for estrone production in women.in: Gual C. Progress in endocrinology: Excerpta Medica. 1969: 770-776
- Steroid prehormones.Perspect Biol Med. 1968; 11: 384-421
- Concentration of unconjugated estrone and estradiol in peripheral plasma in nonpregnant women throughout the menstrual cycle, castrate and postmenopausal women and in men.J Clin Endocrinol Metab. 1969; 29: 149-156
- The role of lipoproteins in the regulation of progesterone secretion by the human corpus luteum.Fertil Steril. 1982; 38: 303-311
- The physiology and pathology of the female reproductive axis.in: Melmed S. Polonsky K.S. Larsen P.R. Kronenberg H.M. Williams textbook of endocrinology. 12th ed. Elsevier, Philadelphia2011: 581-660
- The saga of the ring B unsaturated equine estrogens.Endocr Rev. 1988; 9: 396-416
- Biosynthesis, transport, and metabolism of steroid hormones.in: Henderson B.E. Ponder B. Ross R.K. Hormones, genes, and cancer. Oxford University Press, Inc., New York2003: 12-37
- Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta.Endocrinology. 2008; 149: 4857-4870
- Steroidogenic acute regulatory protein (StAR) is a sterol transfer protein.J Biol Chem. 1998; 273: 26285-26288
- Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR.J Steroid Biochem Mol Biol. 1999; 69: 131-141
- Localization of the steroidogenic acute regulatory protein in human tissues.J Clin Endocrinol Metab. 1997; 82: 4243-4251
- Steroidogenic factor 1 (SF-1) is essential for ovarian development and function.Mol Cell Endocrinol. 2000; 163: 27-32
- Human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5���4-ene-isomerase: purification from mitochondria and kinetic profiles, biophysical characterization of the purified mitochondrial and microsomal enzymes.J Steroid Biochem. 1989; 33: 209-217
- Biogenesis of estrogens by the human ovary. I. Conversion of acetate-1-C-14 to estrone and estradiol.J Biol Chem. 1961; 236: 705-709
- Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis.Endocr Rev. 1994; 15: 342-355
- Steroid formation by isolated and recombined ovarian granulosa and tehcal cells.J Clin Endocrinol Metab. 1968; 28: 355-358
- Conversion of androstenedione to estrone by human tissue.J Clin Endocrinol Metab. 1972; 35: 627-630
- Aromatization of androgens by human abdominal and breast fat tissue.J Clin Endocrinol Metab. 1975; 40: 367-372
- The interconversion and aromatization of androgens by human adipose tissue.J Steroid Biochem. 1979; 10: 623-627
- Aromatization of androstenedione by isolated human hairs.J Clin Endocrinol Metab. 1975; 40: 413-417
- Aromatization of androstenedione by cultured human fibroblasts.J Clin Endocrinol Metab. 1976; 43: 785-795
- Aromatization of androstenedione by the diencephalon.J Clin Endocrinol Metab. 1971; 33: 368-370
- Aromatization of androgens by muscle and adipose tissue in vivo.J Clin Endocrinol Metab. 1978; 46: 146-152
- Role of extraglandular estrogen in human endocrinology.in: Greep R.O. Astwood E.B. Handbook of physiology. Williams and Wilkins, Washington, DC1973: 615-629
- Studies on the secretion and interconversion of the androgens.Recent Prog Horm Res. 1963; 19: 275-310
- Plasma precursors of estrogen. III. Conversion of plasma dehydroisoandrosterone to estrogen in young nonpregnant women.Gynecol Invest. 1976; 7: 165-175
- Metabolic clearance rates and interconversions of estrone and 17beta-estradiol in normal males and females.J Clin Invest. 1968; 47: 93-106
- Sex-hormone-binding globulin.Clin Endocrinol (Oxf). 1974; 3: 69-96
- The serum transport of steroid hormones.Recent Prog Horm Res. 1982; 38: 457-510
- Steroid Binding to Human SBP.in: Westphal U. Steroid-protein interactions II. Monographs on Endocrinology. Vol 27. Springer Verlag, New York1986: 250-259
- Transport of protein-bound hormones into tissues in vivo.Endocr Rev. 1981; 2: 103-123
- Free and protein-bound plasma estradiol-17 beta during the menstrual cycle.J Clin Endocrinol Metab. 1976; 43: 436-445
- Transport of equine estrogens: binding of conjugated and unconjugated equine estrogens with human serum proteins.J Clin Endocrinol Metab. 1985; 61: 499-507
- Obesity, insulin, sex steroids and ovulation.Int J Obes Relat Metab Disord. 2000; 24: S71-S73
- Adipose tissue as a source of hormones.Am J Clin Nutr. 1987; 45: 277-282
- Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism.Proc Soc Exp Biol Med. 1998; 217: 6-16
- Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.J Steroid Biochem Mol Biol. 2003; 86: 477-486
- Active metabolites and carcinogenesis.in: Kono S. Merriam G.R. Brandon D.D. Catechol estrogens. Raven Press, New York1983: 123-140
- Estrogen carcinogenesis in hamster tissues: a critical review.Endocr Rev. 1990; 11: 524-531
- The carcinogenic activity of ethinyl estrogens is determined by both their hormonal characteristics and their conversion to catechol metabolites.Endocrinology. 1993; 132: 577-583
- 2-Hydroxyestrone: the ���good��� estrogen.J Endocrinol. 1996; 150: S259-S265
- Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention.Biochim Biophys Acta. 2006; 1766: 63-78
- Abnormal oxidative metabolism of estradiol in women with breast cancer.Proc Natl Acad Sci USA. 1982; 79: 3047-3051
- Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans.Proc Natl Acad Sci USA. 1985; 82: 6295-6299
- Interaction of histones with estrogens. Covalent adduct formation with 16 alpha-hydroxyestrone.Biochemistry. 1985; 24: 8017-8021
- Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization.Proc Natl Acad Sci USA. 1988; 85: 7831-7835
- Urinary estrogen metabolites and breast cancer: a case���control study.Cancer Epidemiol Biomarkers Prev. 1997; 6: 505-509
- Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.Epidemiology. 2000; 11: 635-640
- A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer.Environ Health Perspect. 1997; 105: 601-605
- Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.J Natl Cancer Inst. 1999; 91: 1067-1072
- Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women.Breast Cancer Res Treat. 2002; 72: 139-143
- Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women?.Cancer Res. 2001; 61: 3326-3329
- Intermediates in the transformation of oral estradiol.J Clin Endocrinol Metab. 1969; 29: 41-46
- Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol.Arzneimittelforschung. 1993; 43: 966-973
- Bioavailability of four oestradiol suspensions with different particle sizes - in vivo/in vitro correlation.Drug Dev Ind Pharm. 1981; 7: 289-303
- The metabolism of estradiol; oral compared to intravenous administration.J Steroid Biochem. 1985; 23: 1065-1070
- Biliary excretion and intestinal metabolism of progesterone and estrogens in man.J Steroid Biochem. 1980; 13: 231-244
- Steroid absorption and enterohepatic recycling.Contraception. 1979; 20: 201-223
- Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens.in: Ottel M. Schillinger E. Estrogens and antiestrogens II. Springer-Verlag, Berlin1999: 261-322
- Estrogen metabolism.in: Sciarra J.J. Reproductive endocrinology, infertility and genetics. Harper & Row, Philadelphia (Pa)1987
- Estrogens used for replacement therapy in postmenopausal women.Gynecol Endocrinol. 2001; 15: 17-25
- Pharmacokinetics and biotransformation of estradiol valerate in ovariectomized women.Horm Res. 1985; 21: 145-154
- Pharmacokinetic and pharmacological features of oestradiol valerate.Maturitas. 1982; 4: 315-324
- Studies on phenolic steroids in human subjects. II. The metabolic fate and hepato-biliary-enteric circulation of C14-estrone and C14-estradiol in women.J Clin Invest. 1957; 36: 1266-1278
- Pharmacokinetics of ethynyloestradiol in humans.Methods Find Exp Clin Pharmacol. 1982; 4: 133-141
- Interindividual variation in the metabolism of ethynylestradiol.Pharmacol Ther. 1989; 43: 251-260
- Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ���low-dose��� pills really lower?.Contraception. 1989; 40: 269-284
- Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.J Steroid Biochem. 1990; 35: 313-318
- Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.Contraception. 1993; 47: 263-281
- Plasma levels of ethinylestradiol (EE) during cyclic treatment with combined oral contraceptives.Contraception. 1981; 24: 589-602
- Metabolism of 17 alpha-ethynylestradiol in humans.Life Sci. 1990; 47: 1981-1988
- Pharmacology of contraceptive steroids: a brief review.Am J Obstet Gynecol. 1989; 160: 1260-1264
- Bio-availability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SH B 209 AB).Contraception. 1976; 14: 151-163
- Metabolism of ethynyloestradiol in man.J Endocrinol. 1972; 55: 351-361
- Fate of ingested radiolabeled ethynylestradiol and its 3-cyclopentyl ether in patients with bile fistulas.J Clin Endocrinol Metab. 1969; 29: 1051-1061
- International Union of Pharmacology. LXIV. Estrogen receptors.Pharmacol Rev. 2006; 58: 773-781
- The molecular determinants of estrogen receptor pharmacology.Maturitas. 2004; 48: S7-S12
- Cloning of a novel receptor expressed in rat prostate and ovary.Proc Natl Acad Sci USA. 1996; 93: 5925-5930
- The steroid and thyroid hormone receptor superfamily.Science. 1988; 240: 889-895
- The nuclear receptor superfamily: the second decade.Cell. 1995; 83: 835-839
- Biological role of estrogen and estrogen receptors.Crit Rev Biochem Mol Biol. 2002; 37: 1-28
- 17 Alpha-ethinyl estradiol is more potent than estradiol in receptor interactions with isolated hepatic parenchymal cells.Endocrinology. 1981; 108: 1511-1518
- Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.N Engl J Med. 1983; 308: 862-867
- Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.Am J Obstet Gynecol. 1988; 158: 1612-1620
- The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.N Engl J Med. 1990; 323: 1375-1381
- Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial.Obstet Gynecol. 1988; 71: 33-38
- Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial.Am J Obstet Gynecol. 1989; 160: 1269-1280
- The effect of triphasic oral contraceptives on plasma lipids and lipoproteins.Am J Obstet Gynecol. 1989; 161: 1396-1401
- Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism.Am J Obstet Gynecol. 1990; 163: 358-362
- Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations.Am J Obstet Gynecol. 1990; 163: 370-373
- Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: a twenty-four month clinical trial.Am J Obstet Gynecol. 1999; 181: 59-62
- Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.Int J Fertil Menopausal Stud. 1995; 40: 98-104
- Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism.Contraception. 1998; 57: 189-201
- Coronary atherosclerosis and myocardial infarction in young women���role of oral contraceptives.Eur Heart J. 1983; 4: 1-6
- Myocardial infarction, oral contraception, cigarette smoking, and coronary artery spasm in young women.Am Heart J. 1983; 106: 757-761
- Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study.BMJ. 1989; 298: 165-168
- Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins.Obstet Gynecol. 1993; 81: 1034-1047
- The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.Contraception. 1997; 56: 129-140
- Myocardial infarction and cigarette smoking in women younger than 50 years of age.JAMA. 1985; 253: 2965-2969
- Smoking and mortality among older men and women in three communities.N Engl J Med. 1991; 324: 1619-1625
- Oral contraceptives and smoking, current considerations: recommendations of a consensus panel.Am J Obstet Gynecol. 1999; 180: S383-S384
- U S. medical eligibility criteria for contraceptive use.MMWR. 2010; 59: 1-88
- Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use.Am J Hematol. 2008; 83: 97-102
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17��-oestradiol in comparison to levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism.Eur J Contracept Reprod Health Care. 2011; 16: 444-457
- Metabolic effects of Envoid in rheumatoid patients.Arthritis Rheum. 1963; 6: 796-800
- Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism.Lancet. 1979; 1: 1045-1049
- Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease.Am J Obstet Gynecol. 1990; 163: 334-343
- A prospective study of oral contraceptives and NIDDM among U.S. women.Diabetes Care. 1997; 20: 330-335
- Oral contraceptive use and glucose metabolism in a national sample of women in the united states.Am J Obstet Gynecol. 2000; 183: 389-395
- An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables.Contraception. 2002; 65: 215-221
- A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.Contraception. 2005; 71: 111-117
- Vascular actions of estrogens: functional implications.Pharmacol Rev. 2008; 60: 210-241
- The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function.Vascul Pharmacol. 2011; 55: 17-25
- Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women.Ann Intern Med. 1994; 121: 936-941
- Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women.Arterioscler Thromb Vasc Biol. 2007; 27: 1782-1787
- Effects of oral contraceptives on vascular endothelium in premenopausal women.Am J Obstet Gynecol. 2000; 183: 28-33
- Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers.Contraception. 2001; 64: 357-362
- Blood pressure alters during the normal menstrual cycle.Br J Obstet Gynaecol. 1986; 93: 523-526
- Prospective study of oral contraceptives and hypertension among women in the United States.Circulation. 1996; 94: 483-489
- The effect of the contraceptive pill on blood pressure: a randomized controlled trial of three progestogen-oestrogen combinations in Szeged, Hungary.Contraception. 1986; 33: 69-77
- Effect of four combined oral contraceptives on blood pressure in the pill-free interval.Contraception. 1993; 47: 367-376
- Oral contraceptives, clotting factors, and thrombosis.Am J Obstet Gynecol. 1982; 142: 758-761
- Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.Am J Obstet Gynecol. 1990; 163: 396-403
- Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.Am J Obstet Gynecol. 1992; 167: 1255-1261
- Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives.Contraception. 1995; 51: 53-58
- The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study.Contraception. 2003; 67: 173-185
- Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.Thromb Haemost. 2011; 105: 560-567
- Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.Clin Drug Investig. 2011; 31: 573-584
- Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives.Contraception. 1994; 49: 579-592
- Hemostatic effects of smoking and oral contraceptive use.Am J Obstet Gynecol. 1999; 180: S369-S374
- Endocrine regulation of the growth plate.Horm Res. 2005; 64: 157-165
- Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial.JAMA. 2003; 290: 1042-1048
- A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.Bone. 1999; 24: 517-523
- A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group.Obstet Gynecol. 1999; 94: 330-336
- Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.Obstet Gynecol. 2004; 104: 443-451
- The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial.Maturitas. 2007; 57: 370-381
- Estrogens, bone loss and preservation.Osteoporos Int. 1990; 1: 7-13
- Evidence of estrogen receptors in normal human osteoblast-like cells.Science. 1988; 241: 84-86
- Low-dose oral contraceptives in adolescents: how low can you go?.J Pediatr Adolesc Gynecol. 2010; 23: 195-201
- Oral contraceptive use and bone.Curr Osteoporos Rep. 2011; 9: 6-11
- Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17beta-estradiol in comparison to levonorgestrel/ethinylestradiol.Acta Obstet Gynecol Scand. 2012; 91: 1279-1285
- Nervous system.in: Goldzieher J.W. Fotherby K. Pharmacology of the contraceptive steroids. Raven Press, Ltd., New York1994: 283-298
- The role of progesterone in menstrual migraine.Neurology. 1971; 21: 853-859
- Transdermal hormonal therapy in perimenstrual migraine: why, when and how?.Curr Pain Headache Rep. 2012; 16: 467-473
- The relationship of oral contraception to depressive symptoms.Aust N Z J Obstet Gynaecol. 1973; 13: 115-120
- Hormonal contraception and mental health: results of a population-based study.Hum Reprod. 2011; 26: 3085-3093
- Combined oral contraceptives and liver disease.Contraception. 1997; 55: 145-151
- Comparison of pharmacodynamic properties of various estrogen formulations.Am J Obstet Gynecol. 1982; 144: 511-518
- Combined oral contraceptive pills for treatment of acne.Cochrane Database Syst Rev. 2012; 7: CD004425
- Effect of low-dose oral contraceptives on androgenic markers and acne.Contraception. 1999; 60: 255-262
- Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones.CNS Spectr. 2001; 6: 783-786
- Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs.Epilepsy Behav. 2011; 21: 453-458
- The use of hormonal contraception among women taking anticonvulsant therapy.Contraception. 2011; 83: 16-29
- Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations.Epilepsia. 2005; 46: 1414-1417
- Oral contraceptive efficacy and antibiotic interaction: a myth debunked.J Am Acad Dermatol. 2002; 46: 917-923
- Antibiotics and oral contraceptive failure ��� a case���crossover study.Contraception. 2011; 83: 418-425
- Drug interactions between oral contraceptives and antibiotics.Obstet Gynecol. 2001; 98: 853-860
- The effects of smoking on estradiol metabolism.Minerva Ginecol. 2004; 56: 105-114
- Smoking, estradiol metabolism and hormone replacement therapy.Arzneimittelforschung. 2003; 53: 1-11
- Female sex and oral contraceptive use accelerate nicotine metabolism.Clin Pharmacol Ther. 2006; 79: 480-488
- Effect of oral contraceptives containing 20 and 35 micrograms ethinyl estradiol on urinary prostacyclin and thromboxane metabolite levels in smokers and nonsmokers.Contraception. 1999; 59: 17-23
- Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.Br J Clin Pharmacol. 1998; 46: 111-116
- Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi.J Acquir Immune Defic Syndr. 2011; 58: e40-e43
- ���The rabbits are prepared ������ ��� The development of ethinylestradiol and ethinyl testosterone.J Reprod Med Endo. 2011; 8: 32-57
- Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations.Contraception. 1999; 60: 321-329
- The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhoea.Eur J Contracept Reprod Health Care. 2007; 12: 354-361
- Contraceptives and cerebral thrombosis: a five-year national case���control study.Contraception. 2002; 65: 197-205
- Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis.J Clin Endocrinol Metab. 2005; 90: 3863-3870
- Recent studies confirm the safety of oral contraceptives with respect to stroke.Contracept Rep. 1996; 7: 4-9
- Oral contraceptive use and myocardial infarction.Contraception. 1998; 57: 143-155
- The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.Contraception. 2007; 75: 344-354
- First-time use of newer oral contraceptives and the risk of venous thromboembolism.Contraception. 1997; 56: 141-146
- Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations.Br J Haematol. 2007; 139: 289-296
- Effect of age on oral contraceptive-induced venous thrombosis.Clin Appl Thromb Hemost. 2004; 10: 259-263
- Hormonal contraception and risk of venous thromboembolism: national follow-up study.Br Med J. 2009; 339: b2890
- The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case���control study.Br Med J. 2009; 339: b2921
- Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.Hum Reprod. 2000; 15: 817-821
- Population-based study of risk of venous thromboembolism associated with various oral contraceptives.Lancet. 1997; 349: 83-88
- The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.Contraception. 1998; 57: 67-70
- 50 years of ���The Pill���: celebrating a golden anniversary.J Fam Plann Reprod Health Care. 2010; 36: 231-238
- Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies.J Fam Plann Reprod Health Care. 2010; 36: 33-38
- Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009.J Fam Plann Reprod Health Care. 2010; 36: 117-122
- Appearance of mammary cancers in male mice subjected to folliculin injections.Comptes Rendus de l'Academie des Sciences. 1932; 195: 630-632
- On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases.Lancet. 1896; 2: 104-107
- Menopause and breast cancer risk.J Natl Cancer Inst. 1972; 48: 605-613
- Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study.Am J Epidemiol. 2000; 152: 950-964
- Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer.Contraception. 1996; 54: 1S-106S
- Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.Lancet. 1996; 347: 1713-1727
- A case���control study of the risk of breast cancer in relation to oral contraceptive use.Am J Epidemiol. 1992; 136: 1437-1444
- Oral contraceptives and the risk of breast cancer.N Engl J Med. 2002; 346: 2025-2032
- The epidemiology of benign breast disease.Epidemiol Rev. 1981; 3: 184-202
- Epidemiology and endocrinology of benign breast disease.Breast Cancer Res Treat. 1985; 6: 5-36
- Risk factors for benign breast disease.Am J Epidemiol. 1981; 113: 203-214
- Oral contraceptives and risk of benign proliferative epithelial disorders of the breast.Int J Cancer. 1992; 50: 891-894
- A cohort study of oral contraceptive use and risk of benign breast disease.Int J Cancer. 1999; 82: 191-196
- Oral contraceptives and benign breast disease: an update of findings in a large cohort study.Contraception. 2007; 76: 418-424
- Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?.Cancer Res. 1997; 57: 3678-3681
- Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.J Natl Cancer Inst. 2002; 94: 1773-1779
- Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.Cancer Epidemiol Biomarkers Prev. 2005; 14: 350-356
- Mortality among oral contraceptive users: 20 year follow up of women in a cohort study.BMJ. 1989; 299: 1487-1491
- Oral contraceptives and survival in breast cancer patients aged 20 to 54 years.Cancer Epidemiol Biomarkers Prev. 2007; 16: 1822-1827
- Oral contraceptives and the risk of death from breast cancer.Obstet Gynecol. 2007; 110: 793-800
- Bias in the evaluation of low-magnitude associations: an empirical perspective.Am J Epidemiol. 2000; 151: 939-945
- Non-contraceptive benefits of oral contraceptives.Expert Opin Pharmacother. 2008; 9: 2317-2325
- Hormonal contraception and risk of endometrial cancer: a systematic review.Endocr Relat Cancer. 2010; 17: R263-R271
- The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development.N Engl J Med. 1987; 316: 650-655
- Speroff L. Fritz M.A. Clinical gynecologic endocrinology and infertility. 7th ed. Lippincott Williams & Wilkins, Philadelphia, PA2005: 691
- Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.Lancet. 2007; 370: 1609-1621
- Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study.BMJ. 2010; 340: c927
Article info
Publication history
Footnotes
���Notes: Frank Z. Stanczyk is a consultant for Agile Therapeutics and Merck & Co., Inc. (formerly Schering Plough, N.V. Organon), and has consulted for Bayer Healthcare and Shionogi. David F. Archer is a consultant for Agile Therapeutics; Bayer Healthcare; CHEMO; Depomed; HRA Pharma; Merck & Co., Inc.; Shionogi; Warner Chilcott; Watson Pharmaceuticals and Wyeth Laboratories (now Pfizer Inc.). He has received research support from Bayer Healthcare; Duramed; Merck & Co., Inc.; Warner Chilcott; Watson Pharmaceuticals and Wyeth Laboratories (now Pfizer Inc) and has received direct lecture fees from Bayer Healthcare; Merck & Co., Inc.; and Wyeth Laboratories (now Pfizer Inc.). Bhagu Bhavnani has nothing to disclose.